Literature DB >> 33941395

SH3BP2-related fibro-osseous disorders of the maxilla and mandible: A systematic review.

J Kueper1, C Tsimbal2, B R Olsen3, L Kaban4, E C Liao5.   

Abstract

Cherubism is a disorder of bony overgrowth of the jaws that manifests in childhood. SH3BP2 gene variants have been associated with cherubism; this gene plays a major role in bone homeostasis. Due to its rare occurrence, there is as yet no comprehensive understanding of the natural history and clinical course of the disease. The aim of this review was to compile and analyze all cases of SH3BP2-related cherubism and cherubism-like disorders. Thirty publications were identified, including 92 individuals from 34 families, who were diagnosed with SH3BP2-related fibro-osseous lesions of the jaw. Only 15% of cases included in this review had no known family history of the disease. The distribution of cherubism was equal with respect to biological sex. Missing teeth were reported in 38% of cases. Lesions were restricted to the mandible in 36% of cases and involved both the maxilla and mandible in 54% of cases. The clinical phenotypes reported in the articles analyzed varied greatly in detail, making comparisons between studies and conclusive analysis difficult. Further work is necessary to describe the connection between SH3BP2 gene variants and cherubism in order to advance its diagnosis and treatment.
Copyright © 2021 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone diseases; Cherubism; Craniofacial abnormalities; Genetic diseases; Jaw diseases

Mesh:

Substances:

Year:  2021        PMID: 33941395     DOI: 10.1016/j.ijom.2021.04.001

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  1 in total

1.  Imatinib has minimal effects on inflammatory and osteopenic phenotypes in a murine cherubism model.

Authors:  Tomoyuki Mukai; Takahiko Akagi; Sumie Hiramatsu Asano; Ikue Tosa; Mitsuaki Ono; Mizuho Kittaka; Yasuyoshi Ueki; Ayano Yahagi; Masanori Iseki; Toshitaka Oohashi; Katsuhiko Ishihara; Yoshitaka Morita
Journal:  Oral Dis       Date:  2021-11-07       Impact factor: 4.068

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.